sibutramine has been researched along with Blood Pressure, High in 50 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Excerpt | Relevance | Reference |
|---|---|---|
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 9.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Sibutramine induced greater weight reduction than placebo (6." | 9.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "The use of sibutramine caused weight loss and a reduction in left ventricular mass in obese and hypertensive patients with no interference with blood pressure or with antihypertensive therapy." | 9.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 9.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 9.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "In obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance." | 9.09 | Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000) |
| "Sibutramine is a drug that is used in the treatment of obesity." | 7.73 | Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. ( Carducci, B; Caruso, A; Cavaliere, AF; De Santis, M; Straface, G, 2006) |
| "Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Obesity is the one of the fundamental problems in societies of the highly developed countries." | 6.42 | [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004) |
| " Concerns over potential pressor effects with sibutramine are reflected in the manufacturer's dosage and administration recommendations." | 6.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 5.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 5.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Sibutramine is an effective appetite suppresser agent, but treatment is often complicated with side effects, including palpitations and hypertension." | 5.11 | Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. ( Baykan, M; Durmus, I; Erem, C; Ersoz, HO; Hacihasanoglu, A; Telatar, M; Ukinc, K, 2004) |
| "Sibutramine induced greater weight reduction than placebo (6." | 5.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors." | 5.11 | Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005) |
| "Sibutramine, a serotonin and norepinephrine transporter blocker, is a common adjunctive obesity treatment." | 5.11 | Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. ( Birkenfeld, AL; Jordan, J; Luft, FC; Pischon, T; Schroeder, C; Sharma, AM; Tank, J, 2005) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 5.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 5.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "The use of sibutramine caused weight loss and a reduction in left ventricular mass in obese and hypertensive patients with no interference with blood pressure or with antihypertensive therapy." | 5.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "In obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance." | 5.09 | Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000) |
| "To compare weight loss efficacy, safety and tolerability of sibutramine and placebo in mildly to moderately obese hypertensive subjects; to assess the effect of weight loss on blood pressure." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. ( Hazenberg, BP, 2000) |
| "- changes in systolic and/or diastolic blood pressure - body weight reduction even though sibutramine and rimonabant have been withdrawn from the market." | 4.89 | Long-term effects of weight-reducing drugs in hypertensive patients. ( Berghold, A; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A; Siering, U, 2013) |
| "Randomized controlled trials in adult hypertensive patients with a study duration of at least 24 weeks comparing pharmacologic interventions (orlistat, sibutramine, rimonabant) for weight loss with placebo." | 4.85 | Long-term effects of weight-reducing drugs in hypertensive patients. ( Berghold, A; Horvath, K; Jeitler, K; Matyas, E; Pignitter, N; Siebenhofer, A; Siering, U; Stich, AK, 2009) |
| "In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension." | 3.77 | [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. ( Madsbad, S, 2011) |
| "Sibutramine, a serotonin and norepinephrine transporter inhibitor, is widely used as an adjunctive obesity treatment." | 3.73 | Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. ( Hauner, H; Jordan, J; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2005) |
| "Sibutramine is a drug that is used in the treatment of obesity." | 3.73 | Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. ( Carducci, B; Caruso, A; Cavaliere, AF; De Santis, M; Straface, G, 2006) |
| "Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate." | 2.73 | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP; Nakou, E; Tselepis, AD, 2008) |
| "Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment." | 2.71 | Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Murdolo, G; Piccinni, MN, 2005) |
| "Obesity is a multifactorial chronic disorder which comprises a serious health problem nowadays." | 2.44 | Sibutramine-associated adverse effects: a practical guide for its safe use. ( Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008) |
| "Reduction of BP was higher in patients treated with weight loss diets (systolic BP [SBP]: weighted mean difference [WMD], -6." | 2.44 | Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. ( Gratzer, TW; Horvath, K; Jeitler, K; Siebenhofer, A; Siering, U; Skipka, G; Stich, AK, 2008) |
| " By subgroup analysis, the effect sizes on weight loss were significantly larger when the dosage was > or = 15 mg." | 2.42 | Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. ( Jee, SH; Kim, SH; Lee, YM; Nam, CM, 2003) |
| "Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management." | 2.42 | Clinical use of sibutramine. ( Ryan, DH, 2004) |
| "Obesity is the one of the fundamental problems in societies of the highly developed countries." | 2.42 | [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004) |
| "Obesity and hypertension are closely associated risk factors for cardiovascular disease." | 2.41 | Sibutramine in overweight/obese hypertensive patients. ( Sharma, AM, 2001) |
| "Sibutramine is a centrally acting inhibitor of noradrenaline and serotonine reuptake, thereby decreasing caloric intake and increasing energy expenditure." | 2.41 | Current pharmacological approaches to the treatment of obesity. ( Hauner, H, 2001) |
| "Overweight and obesity have not only a significant psychological impact but also result in an increased risk for development of numerous chronic and sometimes fatal diseases." | 2.41 | Epidemiology, morbidity, and treatment of overweight and obesity. ( Aronne, LJ, 2001) |
| " Concerns over potential pressor effects with sibutramine are reflected in the manufacturer's dosage and administration recommendations." | 2.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 1.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (8.00) | 18.2507 |
| 2000's | 39 (78.00) | 29.6817 |
| 2010's | 7 (14.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dedov, II | 1 |
| Melnichenko, GA | 1 |
| Troshina, EA | 1 |
| Mazurina, NV | 1 |
| Galieva, MO | 1 |
| Siebenhofer, A | 4 |
| Jeitler, K | 4 |
| Horvath, K | 4 |
| Berghold, A | 3 |
| Siering, U | 3 |
| Semlitsch, T | 2 |
| Blankfield, RP | 1 |
| Iftikhar, IH | 1 |
| Posch, N | 1 |
| Meschik, J | 1 |
| Nakou, E | 1 |
| Filippatos, TD | 1 |
| Liberopoulos, EN | 2 |
| Tselepis, AD | 1 |
| Kiortsis, DN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 2 |
| Sharma, AM | 6 |
| Caterson, ID | 2 |
| Coutinho, W | 3 |
| Finer, N | 3 |
| Van Gaal, L | 2 |
| Maggioni, AP | 2 |
| Torp-Pedersen, C | 3 |
| Bacher, HP | 1 |
| Shepherd, GM | 2 |
| James, WP | 2 |
| Stich, AK | 2 |
| Matyas, E | 1 |
| Pignitter, N | 1 |
| Van Gaal, LF | 1 |
| Ge, H | 1 |
| Moran, SA | 1 |
| Gómez-Barrado, JJ | 1 |
| Turégano, S | 1 |
| Garcipérez de Vargas, FJ | 1 |
| Porras, Y | 1 |
| Madsbad, S | 1 |
| Jordan, J | 3 |
| Hauner, H | 3 |
| Kim, SH | 1 |
| Lee, YM | 1 |
| Jee, SH | 1 |
| Nam, CM | 1 |
| Engeli, S | 1 |
| Ersoz, HO | 1 |
| Ukinc, K | 1 |
| Baykan, M | 1 |
| Erem, C | 1 |
| Durmus, I | 1 |
| Hacihasanoglu, A | 1 |
| Telatar, M | 1 |
| Ryan, DH | 1 |
| Rajzer, M | 1 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| Murdolo, G | 1 |
| Piccinni, MN | 1 |
| Fogari, E | 1 |
| Bertone, G | 1 |
| Ciccarelli, L | 1 |
| Fogari, R | 1 |
| Scholze, J | 2 |
| Matiba, B | 1 |
| Wirth, A | 1 |
| Faria, AN | 2 |
| Ribeiro Filho, FF | 2 |
| Kohlmann, NE | 1 |
| Gouvea Ferreira, SR | 1 |
| Zanella, MT | 2 |
| Doggrell, SA | 1 |
| Gaciong, Z | 1 |
| Placha, G | 1 |
| Haynes, WG | 1 |
| Egri, Z | 1 |
| Birkenfeld, AL | 1 |
| Schroeder, C | 1 |
| Pischon, T | 1 |
| Tank, J | 1 |
| Luft, FC | 1 |
| De Santis, M | 1 |
| Straface, G | 1 |
| Cavaliere, AF | 1 |
| Carducci, B | 1 |
| Caruso, A | 1 |
| Yee, BJ | 1 |
| Phillips, CL | 1 |
| Banerjee, D | 1 |
| Caterson, I | 2 |
| Hedner, JA | 1 |
| Grunstein, RR | 1 |
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Williams, B | 1 |
| Maggioni, A | 1 |
| Sharma, A | 1 |
| Brisco, W | 1 |
| Deaton, R | 1 |
| Shepherd, G | 1 |
| James, P | 1 |
| Bodary, PF | 1 |
| Iglay, HB | 1 |
| Eitzman, DT | 1 |
| Florentin, M | 1 |
| Bönner, G | 1 |
| Skipka, G | 1 |
| Gratzer, TW | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| McMahon, FG | 3 |
| Fujioka, K | 2 |
| Singh, BN | 1 |
| Mendel, CM | 2 |
| Rowe, E | 2 |
| Rolston, K | 1 |
| Johnson, F | 2 |
| Mooradian, AD | 1 |
| Hazenberg, BP | 1 |
| Aronne, LJ | 1 |
| Sramek, JJ | 1 |
| Leibowitz, MT | 1 |
| Weinstein, SP | 2 |
| Rowe, ED | 1 |
| Levy, B | 1 |
| Mullican, WS | 1 |
| Toth, PD | 1 |
| Cutler, NR | 1 |
| Ernst, KR | 1 |
| Lerario, DD | 1 |
| Kohlmann, N | 1 |
| Ferreira, SR | 1 |
| Wooltorton, E | 1 |
| Deitel, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effectiveness of Cryotherapy in Slimming of the Abdomen and Saddlebags[NCT04287153] | 30 participants (Actual) | Interventional | 2017-09-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for sibutramine and Blood Pressure, High
| Article | Year |
|---|---|
Long-term effects of weight-reducing drugs in hypertensive patients.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Humans; Hypertensi | 2013 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Fema | 2016 |
Long-term effects of weight-reducing drugs in hypertensive patients.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Female; Humans; Hypertension; Lactones; Ma | 2009 |
Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
Topics: Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Dose-Response Relationship, Drug; Double- | 2003 |
Clinical use of sibutramine.
Topics: Chronic Disease; Clinical Trials as Topic; Contraindications; Cyclobutanes; Female; Humans; Hyperten | 2004 |
[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].
Topics: Animals; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Developed Countries; Diabetes | 2004 |
Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
Topics: Anti-Obesity Agents; Antihypertensive Agents; Appetite Depressants; Cyclobutanes; Humans; Hypertensi | 2005 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
Strategies to reduce vascular risk associated with obesity.
Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; | 2007 |
Sibutramine-associated adverse effects: a practical guide for its safe use.
Topics: Appetite Depressants; Cyclobutanes; Heart Rate; Humans; Hypertension; Obesity; Risk Assessment; Safe | 2008 |
Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Hypertension; Lactones; Obesity; Orlista | 2008 |
Sibutramine. A review of its contribution to the management of obesity.
Topics: Animals; Appetite Depressants; Controlled Clinical Trials as Topic; Cyclobutanes; Energy Intake; Fem | 1998 |
Current pharmacological approaches to the treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlip | 2001 |
Epidemiology, morbidity, and treatment of overweight and obesity.
Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Body Height; Body Mass Index; Body Weight; | 2001 |
Sibutramine in overweight/obese hypertensive patients.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Heart Rate; Humans; Hypertension; Obesity | 2001 |
16 trials available for sibutramine and Blood Pressure, High
| Article | Year |
|---|---|
Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Female; | 2018 |
Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weights and Measures; C-R | 2008 |
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2009 |
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Anthropometry; Appetite Depressants; Arrhythmias, Cardiac; Cyclo | 2004 |
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Topics: Analysis of Variance; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Femal | 2005 |
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Chi-Square Distribution; Cyclobutanes; Drug Th | 2005 |
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia | 2005 |
Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Arrhythmias, Cardiac; Autonomic Nervous System; Baror | 2005 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
Topics: Aged; Appetite Depressants; Cyclobutanes; Diabetic Angiopathies; Double-Blind Method; Female; Humans | 2007 |
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Aged; Appetite Depressants; Black People; Body Weight; Cyclobutanes; Double-Blind Method; Fem | 2000 |
Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Cyclobutanes; Diastole; Double-Blin | 2000 |
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Appetite Depressants; Benzothiadiazines; Blood Pressure; C | 2002 |
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Appetite Depressants; Benzothiadiazines; Blood Pres | 2002 |
Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
Topics: Antihypertensive Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Dr | 2002 |
19 other studies available for sibutramine and Blood Pressure, High
| Article | Year |
|---|---|
Food and drug administration regulation of drugs that raise blood pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cyclobutanes; Drug Approval; Humans; Hypert | 2015 |
Acute coronary syndrome in a young woman treated with sibutramine.
Topics: Acute Coronary Syndrome; Adult; Anti-Obesity Agents; Cyclobutanes; Female; Humans; Hypertension; Myo | 2010 |
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobuta | 2011 |
Potential for sibutramine-yohimbine interaction?
Topics: Animals; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyclobutanes; Drug Interactions; Humans; H | 2003 |
[A drug help in reducing? Risk profile decides whether and how].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Diab | 2003 |
[What effect does losing weight have on hypertension?].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Contraindicati | 2003 |
Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Pressure; Body Mass Ind | 2005 |
Sibutramine and the sympathetic nervous system in obese humans.
Topics: Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Cyclobutanes; Heart Rate; Humans; Hy | 2005 |
Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up.
Topics: Abnormalities, Drug-Induced; Adult; Appetite Depressants; Body Mass Index; Counseling; Cyclobutanes; | 2006 |
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cohort Studies; Cyclobutanes; Heart Rate; Humans; | 2007 |
Acute effects of sibutramine administration on the autonomic nervous system in obese subjects.
Topics: Appetite Depressants; Autonomic Nervous System; Cyclobutanes; Humans; Hypertension; Norepinephrine; | 2007 |
The obese hypertensive: the weight of evidence against beta-blockers.
Topics: Adrenergic beta-Antagonists; Appetite Depressants; Cost-Benefit Analysis; Cyclobutanes; Humans; Hype | 2007 |
[Effect of weight loss on blood pressure].
Topics: Appetite Depressants; Behavior Therapy; Blood Pressure; Body Mass Index; Cyclobutanes; Diet, Reducin | 2007 |
American Heart Association urges caution on new diet drug.
Topics: American Heart Association; Appetite Depressants; Cyclobutanes; Drug Evaluation; Humans; Hypertensio | 1998 |
Sibutramine for obesity.
Topics: Appetite Depressants; Cyclobutanes; Drug Costs; Drug Interactions; Heart Rate; Humans; Hypertension; | 1998 |
New diet drug is not without health risks.
Topics: Appetite Depressants; Cyclobutanes; Humans; Hypertension | 1998 |
Diet drug helps keep weight off.
Topics: Appetite Depressants; Cyclobutanes; Hypertension; Obesity; Weight Loss | 2001 |
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.
Topics: Appetite Depressants; Arrhythmias, Cardiac; Cyclobutanes; Humans; Hypertension; Obesity | 2002 |
Sibutramine warning: hypertension and cardiac arrhythmias reported.
Topics: Appetite Depressants; Arrhythmias, Cardiac; Contraindications; Cyclobutanes; Humans; Hypertension | 2002 |